Analysis of survival rate and influencing factors of Kang'ai injection combined with entecavir in patients with hepatitis B-related hepatocellular carcinoma after TACE
Objective:To explore the impact of administering Kangai injections in conjunction with entecavir on the survival rates of patients afflicted with hepatocellular carcinoma associated with hepatitis B(HBV-HCC)following transcatheter arterial chemoembolization(TACE),and to identify the factors that influence this outcome.Methods:86 patients with HBV-HCC who had been treated with TACE in our hospital were randomly divided into two groups.43 patients in the control group were treated with Intecavir,and 43 patients in the observation group were treated with kang'ai injection combined with Entecavir.Both groups were treated for 12 months and followed up for 5 years.The 3 years and 5 years survival rate and progression-free survival rate of the two groups were compared,the clinical data of the two groups were recorded and compared,and the COX multivariate analysis was used to screen out statistically significant independent risk factors.The Kaplan-Meier method was used to stratified the median survival and median progression-free survival of the two groups according to tumor stage.Results:The 3-year,5-year survival rate and progression-free survival rate of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Univariate analysis showed that clinical stage,portal vein tumor thrombus and treatment plan were the factors affecting the 5-year survival rate of patients with HBV-HCC(P<0.05).COX multivariate analysis showed that clinical stage and treatment plan were independent factors affecting the survival rate of patients with HBV-HCC(P<0.05).Stratified by clinical stage,the median survival time of patients with stageⅡandⅢa in the observation group was longer than that in the control group(13.9 months vs.7.0 months,6.5 months vs.3.4 months,P<0.05).The median progression-free survival of patients with stage Ⅱ and stage Ⅲa in the observation group was higher than that in the control group(10.8 months vs.6.3 years,5.1 months vs.2.7 months),and the difference was statistically significant(P<0.05).Conclusion:Compared with tenofovir,entecavir after TACE did not significantly improve the survival rate and survival cycle of patients with stage Ⅱ～Ⅲ.a HBV-HCC.
NETL
NSTL
万方数据
维普
